Skip to content

A Randomized Comparison Between Intravenous and Perineural Dexamethasone for Ultrasound-Guided Infraclavicular Blocks

A Randomized Comparison Between Intravenous and Perineural Dexamethasone for Ultrasound-Guided Infraclavicular Blocks

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20150624001
Enrollment
150
Registered
2015-06-24
Start date
2015-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infraclavicular block Duration of motor blockade Intravenous dexamethasone Perineural dexamethasone

Interventions

Patients will receive 5 mg of dexamethasone intravenously.,Patients will receive the injectate with 5 mg of dexamethasone through the block needle.
Experimental Drug,Experimental Drug
Intravenous dexamethasone,Perineural dexamethasone

Sponsors

No sponsor
Lead Sponsor
No sponsor
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients undergoing upper extremity surgery (elbow and below) with - American Society of Anesthesiologists classification 1-3 - body mass index between 18 and 35

Exclusion criteria

Exclusion criteria: - adults who are unable to give their own consent - pre-existing neuropathy (assessed by history and physical examination) - coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, or International Normalized Ratio ≥ 1.4) - renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100) - hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100) - allergy to local anesthetics (LAs) - pregnancy - prior surgery in the infraclavicular region - chronic pain syndromes requiring opioid intake at home

Design outcomes

Primary

MeasureTime frame
Duration of the motor block within 48 hours the interval between the end of LA injection and the return of movement to hand and fingers

Secondary

MeasureTime frame
Duration of the sensory block within 48 hours the interval between the end of LA injection and the return of sensation to the hand and fingers,Duration of the analgesia within 48 hours the interval between the end of LA injection and the appearance of pain at the surgical site,Sensory blockade of the musculocutaneous, median, radial and ulnar nerves every 5 minutes until 30 minutes after the procedure a 3-point scale using a cold test: 0 = no block, 1 = analgesia, 2 = anesthesia,Motor blockade of the musculocutaneous, median, radial and ulnar nerves every 5 minutes until 30 minutes after the procedure a 3-point scale: 0 = no block, 1 = paresis, 2 = paralysis ,Success rate for surgical anesthesia at the beginning of the surgery the ability to proceed with surgery without the need for IV narcotics, GA, or LA infiltration,Onset time until 30 minutes after the procedure the time required to reach a minimal score of 14 out of 16 points.,Persistent sensory or motor deficits 7 days after the prpcedure all patients will be contacted by phone,Complications during the procedure and perioperative period vascular puncture, hematoma at the puncture site , toxic effects of LA, hoarseness, Horner syndrome

Countries

Thailand

Contacts

Public ContactVanlapa Arnuntasupakul

Mahidol University

vanlapaa@gmail.com662-201-1523

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026